<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456182</url>
  </required_header>
  <id_info>
    <org_study_id>AFX-2-2010-1</org_study_id>
    <nct_id>NCT01456182</nct_id>
  </id_info>
  <brief_title>Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels
      in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL). The trial
      will also determine the impact of dose on quality of life indices and on biological and
      immune responses, and will assess if there is a maximum tolerated dose and/or dose-limiting
      toxicity in this study population.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed based on the incidence, duration and intensity of adverse events</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>Adverse events will be graded according to NCI-CTC v4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability will also be determined by assessing any changes in study test results from baseline values</measure>
    <time_frame>1 week, 4 weeks, 8 weeks</time_frame>
    <description>Study tests that will determine safety include vital signs, clinical laboratory tests (hematology, serum chemistries, coagulation, urinalysis) and 12-lead EKG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life indices</measure>
    <time_frame>1 week, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose and/or dose-limiting toxicity</measure>
    <time_frame>1 week, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological and immune responses</measure>
    <time_frame>1 week, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Dose arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose arm 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose arm 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose arm 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFX-2</intervention_name>
    <description>Dose level 1</description>
    <arm_group_label>Dose arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFX-2</intervention_name>
    <description>Dose level 2</description>
    <arm_group_label>Dose arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFX-2</intervention_name>
    <description>Dose level 3</description>
    <arm_group_label>Dose arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFX-2</intervention_name>
    <description>Dose level 4</description>
    <arm_group_label>Dose arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFX-2</intervention_name>
    <description>Dose level 5</description>
    <arm_group_label>Dose arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult men and women &gt;18 years of age

          2. Diagnosis of CLL per NCI Working Group Criteria; with phenotypic evidence (i.e.. flow
             cytometry or bone marrow biopsy) of chronic lymphocytic leukemia (MEDDRA Code -
             10008960; ICD-O3-9823)

          3. Disease meets criteria for low-risk (Rai Stage 0), intermediate-risk (Rai Stage I-
             II), or high-risk (Rai Stage III-IV) disease

          4. Life expectancy of ≥ 3 months at Screening.

          5. ECOG performance status 0-3

          6. Laboratory parameters (taken &lt; 14 days of Study Day 0):

               -  Hematologic parameters: Hemoglobin &gt; 9 gm/dL (stable, not dropping); Absolute
                  Granulocyte Count (AGC) &gt; 1.0 x 109/L; Platelets &gt; 50 x 109/L; not requiring
                  immediate transfusion.

               -  Coagulation: PT/PTT/INR: ± 10% of NL for lab; INR: 1.0-1.43

               -  BUN &lt; 40; serum Creatinine ≤ 2.0 mg/dL, OR Creatinine Clearance &gt; 90
                  mL/min/1.73m2 IF serum Creatinine &gt; 2.0 mg/dL

               -  Liver function tests (AST, ALT, ALP, LDH): &lt; 2.5 x institutional ULN; Total
                  bilirubin: &lt; 2.0 x institutional ULN

               -  Human Immunodeficiency Virus (HIV) negative

               -  Pregnancy test: negative urine pregnancy test for females of child-bearing
                  potential,

          7. Free of disease from prior malignancy/ies for &gt; 2 years, except for basal cell or
             squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.

          8. If not surgically sterile, or post-menopausal (&gt; 12 months with no menstrual flow),
             willing to practice birth control (barrier + contraception) throughout duration of
             study.

          9. Able and willing to swallow capsules.

         10. Willing to limit alcohol intake during the study treatment period.

         11. Willing to sign the informed consent.

        Exclusion Criteria:

          1. Lymphoproliferative disease other than CLL

          2. Prior use of the test article (AFX-2), or ginseng-containing products (American,
             Asian, etc.) ≤ 1 year prior to study entry.

          3. Known allergy to the test article or ginseng-containing products

          4. Active infection requiring systemic treatment

          5. Prior or current therapy:

               -  Splenectomy.

               -  Currently requiring anticoagulant therapy

               -  Requiring active treatment for B-CLL or ≤ 28 days post-treatment for B-CLL or
                  other condition requiring: chemotherapy, radiation therapy, monoclonal
                  antibodies, systemic steroids, antihistamines or non-steroidal anti-inflammatory
                  drugs, including ibuprofen, indomethacin, COX-2 inhibitors etc.

               -  ≤ 10 days: non-steroidal hormonal therapy (other than for contraception or
                  thyroid)

               -  ≤ 10 days: antibiotic prophylaxis

               -  History of therapy with immunological reagents, such as allogeneic bone marrow
                  transplant, monoclonal antibody therapy, intravenous immunoglobulin, or
                  hematopoietic stem cell transplantation. (Note: Immunotherapy for allergies is
                  permitted as long as the last treatment was both (a) prior to the CLL diagnosis
                  and (b) &gt; 5 years prior to trial enrollment.)

               -  &lt; 90 days post treatment with chlorambucil

               -  &lt; 90 days post general anesthesia

          6. Uncontrolled intercurrent condition, including, but not limited to, cardiovascular,
             pulmonary, renal, hepatic, GI, GU, neurologic, metabolic, psychiatric, etc.

          7. Current or prior investigational product or procedure &lt; 56 days preceding study entry
             (Baseline -Visit 2; Study Day 0).

          8. Unwilling to discontinue use of nonprescription (OTC), nutritional or dietary
             supplements during the study period (as further defined by protocol).

          9. Pregnant, lactating.

         10. Any condition, personal or social situation that precludes or limits the ability of
             the participant to provide informed consent or comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie R Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Jospeh Mercy Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

